Ben Umiker, et al. Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors. Published in Molecular Cancer Therapeutics February 2023
Contact Us
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
Kim Drapkin
(857) 999-2906 kdrapkin@jouncetx.com